Revance Therapeutics Inc. (NASDAQ:RVNC)’s traded shares stood at 1.18 million during the last session, with the company’s beta value hitting 0.88. At the close of trading, the stock’s price was $31.15, to imply an increase of 1.63% or $0.5 in intraday trading. The RVNC share’s 52-week high remains $36.61, putting it -17.53% down since that peak but still an impressive 63.82% since price per share fell to its 52-week low of $11.27. The company has a valuation of $2.79B, with an average of 1.4 million shares in intraday trading volume over the past 10 days and average of 1.65 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Revance Therapeutics Inc. (RVNC), translating to a mean rating of 2.10. Of 13 analyst(s) looking at the stock, 1 analyst(s) give RVNC a Sell rating. 1 of those analysts rate the stock as Overweight while 2 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.69.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Revance Therapeutics Inc. (NASDAQ:RVNC) trade information
After registering a 1.63% upside in the last session, Revance Therapeutics Inc. (RVNC) has traded red over the past five days. The stock hit a weekly high of 31.38 this Thursday, 03/16/23, jumping 1.63% in its intraday price action. The 5-day price performance for the stock is 0.58%, and -3.86% over 30 days. With these gigs, the year-to-date price performance is 68.74%. Short interest in Revance Therapeutics Inc. (NASDAQ:RVNC) saw shorts transact 12.18 million shares and set a 9.37 days time to cover.
Analysts on Wall Street suggest a consensus price target of $37.54, implying an increase of 17.02% to the stock’s current value. The extremes give us $20.00 and $65.00 for target low and target high price respectively. As such, RVNC has been trading -108.67% off suggested target high and 35.79% from its likely low.
Revance Therapeutics Inc. (RVNC) estimates and forecasts
Looking at statistics comparing Revance Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Revance Therapeutics Inc. (RVNC) shares are 13.15% up over the last 6 months, with its year-to-date growth rate higher than industry average at 43.27% against 9.40%. Revenue is forecast to grow 26.60% this quarter before jumping 23.90% for the next one. The rating firms project that company’s revenue will grow 81.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is $46.28 million. Meanwhile, for the quarter ending Jun 2023, a total of 10 analyst(s) estimate revenue growth to $56.46 million.Earnings reports from the last fiscal year show that sales brought in $25.26 million and $28.37 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 83.20% before jumping 99.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -4.10% for the past 5-year period. While 2023 is set for a -17.60% return in earnings, projections for the next 5 years are at 11.60% annually.
RVNC Dividends
Revance Therapeutics Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Revance Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Revance Therapeutics Inc. (NASDAQ:RVNC)’s Major holders
Revance Therapeutics Inc. insiders hold 2.47% of total outstanding shares, with institutional holders owning 98.25% of the shares at 100.74% float percentage. In total, 98.25% institutions holds shares in the company, led by Capital World Investors. As of Dec 30, 2022, the company held over 9.48 million shares (or 11.45% of shares), all amounting to roughly $295.31 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 7.07 million shares, or about 8.54% of shares outstanding. As of the market price on Dec 30, 2022, these shares were worth $220.35 million.
We also have Smallcap World Fund and New Economy Fund (The) as the top two Mutual Funds with the largest holdings of the Revance Therapeutics Inc. (RVNC) shares. Going by data provided on Dec 30, 2022, Smallcap World Fund holds roughly 6.58 million shares. This is just over 8.00% of the total shares, with a market valuation of $205.09 million. Data from the same date shows that the other fund manager holds a little less at 2.81 million, or 3.42% of the shares, all valued at about 87.53 million.
